Nick Everett

@Kinoxis_Tx is pleased to share that $14.5m in funding has been raised to support Phase 2 programs for lead drug asset KNX100. We would like to thank key investors for sharing and supporting our vision in treating #dementia and #substanceusedisorder. More: kinoxistherapeutics.com/wp-content/upl…

The Growing Minds Check-In (growingmindscheckin.au) has arrived! The Check-In is a free wellbeing check for parents with kids 0-17 years, developed with the best in the biz (1/4)@growingmindsau @UsydPsych @David_J_Hawes @FrankOberklaid @DrDianneShanley @WarrenGCann @AACBT_org_au

Stoked to introduce @BowenLabTweets and his Professorial talk at the @UsydPsych School of Psychology Colloquium, giving a great overview of his leadership in the @Kinoxis_Tx program to develop novel therapies for social and substance use disorders. @BrainMind_Usyd

@NathanJMarchant @ShaunaParkes @NeuroAllison Congrats Ally and Nathan!

The lastest from @jamesheathers - re scientific publishing -- worth a close look. jamesclaims.substack.com/p/the-hindawi-…

@ginevradottavio @TylahDoolan

I'm hugely surprised: these clinical data perfectly align with my preclinical!! 😱😱😱 "analyses suggest a causal relationship between the use of opioids and impaired social behavior, impairments among stimulant users seem to be partially predisposed" doi.org/10.1016/j.bpsc…

Congrats all! Well done @james_wm_kang , looking forward to collaborating with you on this!

We're hiring at @PsyMQ: Lecturer or Senior Lecturer in Psychology (Teaching & Leadership): mq.wd3.myworkdayjobs.com/en-US/Careersa… 2 x Lecturer or Senior Lecturer in Psychology (Balanced 40-40-20): mq.wd3.myworkdayjobs.com/CareersatMQ/jo… mq.wd3.myworkdayjobs.com/CareersatMQ/jo… Applications closing end of July 2024.

We are fortunate to have a great partnership with @samuel_b_phd and the entire @Psylo_Bio team. We are aligned in moving the needle for sufferers of poorly treated disorders. Excellent people, and excellent science! Looking forward to what's ahead 🧠💊 @UsydPsych @BrainMind_Usyd

Super grateful to spend time with these great Aussie behavioural neuroscientists and even better karaoke singers @IBNSconnect #IBNS2024

Happy Friday friends! A new release is out of DLC, which … is the last 2.x release! 🥹🎉🤩 Please update your conda env. with a simple pip upgrade ❤️🎉 What’s changed: 📖 github.com/DeepLabCut/Dee… This also means, v3.0 is coming …. and it’s 🔥🔥🔥

@philJRDB So good! Cya soon ☺️

Took a slight detour on my way to #IBNS2024

@alex_guerin13 @BPA_ECRN @KynaConn 👀👀👀

Excellent opportunity for a grad researcher or an ECR! I had the privilege to give the @BPA_ECRN Plenary last year, and it was an amazing experience! Please feel free to DM me if anyone is thinking of applying/would like me to look over a draft #BPA2024

📢Don't miss tomorrow’s BDI seminar! 𝗦𝗽𝗲𝗮𝗸𝗲𝗿: Dr Nicholas Everett @Neuronick @Sydney_Uni 𝗧𝗼𝗽𝗶𝗰: Psychiatric drug development at the intersection of academia & industry 𝗪𝗵𝗲𝗻: Tue 21 May 2024 12-1pm. In person only. See more: bit.ly/3uCUMgc @ClaireFoldi

@DrSalGainsbury Congrats Tom! Did you graduate Monday? Must have just missed you

Congratulations Dr Tom Swanton! I am so impressed with what you have achieved and feel privileged to have been your Honours and PhD supervisor. Good luck for your next steps!

@MoeNeuro @dr_brein @Jie_Neuro @parnazboroon @TheBorisLab @mCherryGarcia This is a great way to tell the story, thanks! And congrats!

📣 We are seeking a VP/Consultant of Drug Development: Clinical Readiness with CNS/neuro experience. This part-time/consulting role is open to candidates in the US or AU. 🧠🥼 Help create next-generation therapeutics. Join Team Psylo! #Jobs #Hiring linkedin.com/jobs/view/3906…

@KynaConn @LauraKMilton @ClaireFoldi @molpsychiatry @MonashBDI Well done guys!!

Proud to have co-led this important study w/ @LauraKMilton and to finally bring to fruition the pioneering vision of @ClaireFoldi in @molpsychiatry . It has been an honour to work with #psilocybin 🍄 in Australia @MonashBDI nature.com/articles/s4138…

@wmkenkel The former may have more societal impact and is incentivised in industry (and not published), but academia incentives the latter due to pubs and citations (arguably lesser impact for society). As someone that straddles both ind/ac, I'd love to see less of a rift between the two.

It’s weird to me that the biggest issue in neuroscience isn’t “how can we transport drugs across the blood brain barrier for precise regional targeting” but instead “how can we make this microscope smaller and see more calcium sparkles?” ✨

Mainstream psychiatry woke up to the potential medical value of psychedelic research ca. 2016. I suspect 2024 might be the year that mainstream cognitive neuroscience finally wakes up to their scientific value.